What Shin Nippon Biomedical Laboratories (SNBL) does

Shin Nippon Biomedical Laboratories, Ltd. (TYO: 2395), commonly referred to as SNBL, is a Japanese public contract research organization founded in 1957 in Kagoshima and headquartered in Tokyo. It claims the position of Japan's first CRO, with stated operational experience of more than 60 years. The company serves enterprise pharmaceutical clients with drug development outsourcing services spanning preclinical and clinical research support, including study conduct, regulated workflow execution, and quality assurance consistent with long-standing GLP/GCP environments in Japan and overseas markets. SNBL also markets 'translational research' services that bridge preclinical and clinical workstreams, plus a separately branded 'Medipolis' social value creation segment and a residual 'Other Business' line; these last two indicate diversification beyond pure CRO activity. An April 2023 acquisition of Satsuma Pharmaceuticals (and an earlier 2018 acquisition of Trunk Solution) signal a deliberate move up the pharmaceutical value chain beyond fee-for-service contract research.

The business model is B2B enterprise sales to pharmaceutical and biotechnology customers under individually negotiated project-based contracts; pricing is not publicly disclosed. Go-to-market is primarily direct enterprise sales supported by corporate communications across the company's website, LinkedIn, YouTube and an IR blog. Ownership is dispersed through public shareholding under a Japanese listed-company governance structure with formal investor relations and ESG disclosure infrastructure. Recent reported financial trajectory shows revenue variability year-over-year with EBITDA margin compression from 2023 levels, alongside reported acquisition-related expansion.

Name

Shin Nippon Biomedical Laboratories (SNBL)

Legal name

株式会社新日本科学 (Shin Nippon Biomedical Laboratories, Ltd.)

Website

https://snbl.co.jp

Company type

Public

Founded year

1957

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Shin Nippon Biomedical Laboratories (SNBL) is Japan's first contract research organization, founded in 1957 and headquartered in Tokyo. It provides pharmaceutical drug development, translational research, and Medipolis social-value services to enterprise pharmaceutical clients.

Ownership category

akta.pro rank

Product category

Contract Research Organization Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

Keywords

• Contract research organization
• Drug development services
• Preclinical research
• Clinical trial support
• Translational research

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. CRO (Drug Development Outsourcing) Services: Contract research organization services providing comprehensive support for pharmaceutical drug development, including preclinical and clinical trial support
2. Translational Research Services: Research services bridging early discovery and clinical development phases for pharmaceutical clients
3. Medipolis (Social Benefit) Services: Services focused on creating social value and advancing medical technologies for societal benefit

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

SNBL is a contract research organization (CRO) providing drug development support services to pharmaceutical and biotechnology companies. The company operates four main service lines: CRO services (preclinical and clinical research support), Translational Research bridging preclinical and clinical phases, Medipolis Social Benefit Creation initiatives, and Other Business activities. Founded in 1957 as Japan's first CRO, SNBL offers end-to-end drug development capabilities.

Product overview

Shin Nippon Biomedical Laboratories (SNBL) operates as a traditional contract research organization (CRO) offering a platform of pharmaceutical development services. The company provides four main service offerings: CRO drug development contract research services, translational research services, Medipolis (social value creation) services, and other business operations. With over 60 years of experience, SNBL delivers high-quality services and tailored solutions supporting drug discovery and medical technology advancement.

Differentiator

Problem solved

Functional benefit

Brands

• Medipolis: Social benefit creation business segment of SNBL focused on societal benefit initiatives

Products and services

• CRO Services Contract research organization services providing preclinical and clinical drug development support to pharmaceutical and biotechnology companies seeking outsourced research capabilities.
• Translational Research Services Translational research services bridging preclinical and clinical phases of drug development, helping pharmaceutical sponsors translate laboratory findings into clinical applications.
• Medipolis Social Benefit Creation Medipolis initiative focused on social benefit creation through healthcare and research activities, extending SNBL's capabilities beyond traditional CRO services into broader societal healthcare contributions.
• Other Business Services Additional business services beyond core CRO and translational research, supporting diversified offerings to pharmaceutical clients and partners.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators1 record

Recent moves4 records

Expansion highlights5 records

Direct peers

• Parexel: Global CRO providing clinical research, regulatory, and market access services to biopharmaceutical clients; directly comparable to SNBL across drug development outsourcing services.
• Charles River Laboratories: Major preclinical and discovery CRO with strong translational research capabilities, serving pharma and biotech sponsors; directly comparable to SNBL's preclinical CRO and translational research service lines.
• IQVIA: Largest global CRO and clinical research services provider offering preclinical through Phase IV clinical trial services to pharmaceutical and biotech sponsors; directly comparable to SNBL across the full drug development outsourcing stack.
• ICON plc: Global clinical CRO providing full-service clinical development and laboratory services to pharmaceutical sponsors; closely comparable business model and target customer base to SNBL's CRO services.
• Syneos Health: Global biopharmaceutical services organization offering clinical CRO and commercialization services; comparable to SNBL in serving pharma sponsors across drug development outsourcing.
• Medpace: Mid-sized clinical CRO focused on full-service Phase I-IV trial execution for pharma and biotech sponsors; comparable to SNBL's clinical CRO service line with similar mid-cap positioning.
• LabCorp (Covance): Major clinical CRO and central laboratory services provider through its Covance Drug Development business; directly comparable to SNBL in clinical trial support and lab-based drug development services.

Regional players

• EPS Holdings: Japanese CRO and healthcare services group providing clinical development, SMO, and CRO services to pharma sponsors; competes with SNBL primarily in the Japanese market.
• CMIC Holdings: Leading Japanese CRO and pharmaceutical services provider serving domestic pharma sponsors; directly comparable to SNBL as a Japan-headquartered CRO competitor in the same home geography.

Emerging players

• WuXi AppTec: Asia-based contract research, development, and manufacturing organization with broad preclinical-to-clinical capabilities; comparable to SNBL in translational research services and Asia-region pharma outsourcing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/user/SNBLofficial
• LinkedInlinkedin.com/company/snbl-japan

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shin Nippon Biomedical Laboratories (SNBL)